Gelonghui, November 27 | Amgen (AMGN.US) fell more than 2.6% in pre-market trading, reporting $272.64. The stock closed down 4.76% on Tuesday. On the news front, Amgen announced on Tuesday that in a year-long trial, non-diabetic patients taking the weight loss drug MariTide once a month or less could lose up to 20% of their weight. Analysts pointed out that this is comparable to the maximum dose effect of Eli Lilly and Co's Zepbound. However, data shows that the side effects of MariTide are greater than those of Zepbound, with about 11% of patients dropping out of the MariTide trial due to side effects, whereas in Zepbound's phase 3 trial, the dropout rate was around 7%. Amgen responded by stating that nausea and vomiting are usually mild, short-lived, and mainly related to initial dosing, and these symptoms can be addressed by slowing the dosage schedule.